{
  "id": "Crusade_Score_Assessment.v1",
  "gdl_version": "2.0",
  "concept": "gt0001",
  "language": {
    "original_language": "ISO_639-1::en"
  },
  "description": {
    "original_author": {
      "date": "2017-10-05",
      "name": "Syeeda S Farruque",
      "organisation": "Cambio Healthcare Systems",
      "email": "models@cambiocds.com"
    },
    "other_contributors": [
      "Dennis Forslund, Cambio Healthcare Systems",
	  "Aulia Zahrina Qashri"
    ],
    "lifecycle_state": "Author draft",
    "details": {
      "sv": {
        "id": "sv",
        "purpose": "Att med avseende på blödningsrisk riskstratifiera patienter som genomgått STEMI eller NSTEMI i syfte att utgöra understöd för bedömning av behandling.",
        "keywords": [
          "Crusade Score",
          "STEMI",
          "NSTEMI",
          "kardiologi"
        ],
        "use": "CRUSADE är en akronym för Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines. Metoden baseras på åtta parametrar; uppskattad kreatininclearance, vilopuls, systoliskt blodtryck i vila, kön, symtom på hjärtsvikt, tidigare kärlsjukdom, och diabetes mellitus. \n\nResultatet tolkas enligt:\n\n≤20p: mycket låg blödningsrisk (3,1%)\n21-30p: låg blödningsrisk (5,5%)\n31-40p: måttlig blödningsrisk (8,5%)\n41-50p: hög blödningsrisk (11,9%)\n>50p: mycket hög blödningsrisk (19,5%)",
        "misuse": "Ej tillämpbar på patienter med instabil angina pectoris, som behandlas med warfarin, som dog inom 48h från ankomst till sjukhus, eller som flyttades från sjukhuset.",
        "copyright": "© Cambio Healthcare Systems"
      },
      "en": {
        "id": "en",
        "purpose": "CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) score for post MI bleeding risk provides a way to stratify the risk of bleeding for patients after NSTEMI and STEMI in order to guide treatment",
        "keywords": [
          "Crusade score for post mi bleeding risk",
          "Myocardial infarction",
          "NSTEMI",
          "STEMI"
        ],
        "use": "This tool allows for interpretation of the scores. The score identifies:\n\nVery low risk (3.1% risk of major bleeding) as bleeding score ≤20, \nLow risk (5.5%) with a score range of 21-30\nModerate risk (8.5%) with a score range of 31-40\nHigh risk (11.9%) with a score range of 41-50\nVery high risk (19.5%) with scores >50.\n\nRecommendations:\n\nVery High Risk: Judicious use of anti-thrombotic and invasive therapies is prudent in this very high risk of bleeding group. \n\nHigh risk: Judicious use of anti-thrombotic and invasive therapies is prudent in this high risk of bleeding group. \n\nModerate risk: Initiation of anti-thrombotic and invasive therapies should be considered and discussed with the patient as the benefits likely outweigh the risks.\n\nLow Risk: Initiation of anti-thrombotic and invasive therapies should be considered as benefits likely outweigh the risks. \n\nVery Low Risk: Initiation of anti-thrombotic and invasive therapies is reasonable given a relatively low risk of major bleeding.",
        "misuse": "Do not use on  patients with unstable angina, those taking warfarin at home, died within 48 hours of hospital arrival, and those transferred out of a CRUSADE hospital.",
        "copyright": "© Cambio Healthcare Systems"
      }
    },
    "other_details": {
      "references": "Ref. 1: Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, Pollack CV Jr.,Peterson ED, Alexander KP. Baseline risk of major bleeding in non‐ST‐segment‐elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early Implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009; 119:1873-1882\n\nRef. 2: Ariza-Solé A, Sánchez-Elvira G, Sánchez-Salado JC, et al. CRUSADE bleeding risk score validation for ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Thromb Res 2013; 132(6):652-8."
    }
  },
  "definition": {
    "data_bindings": {
      "gt0003": {
        "id": "gt0003",
        "model_id": "openEHR-EHR-OBSERVATION.crusade_score_for_post_mi_bleeding_risk.v1",
        "template_id": "openEHR-EHR-OBSERVATION.crusade_score_for_post_mi_bleeding_risk.v1",
        "type": "INPUT",
        "elements": {
          "gt0006": {
            "id": "gt0006",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0012]"
          }
        }
      },
      "gt0018": {
        "id": "gt0018",
        "model_id": "openEHR-EHR-EVALUATION.crusade_bleeding_score_assessment.v1",
        "template_id": "openEHR-EHR-EVALUATION.crusade_bleeding_score_assessment.v1",
        "type": "OUTPUT",
        "elements": {
          "gt0019": {
            "id": "gt0019",
            "path": "/data[at0001]/items[at0002]"
          },
          "gt0020": {
            "id": "gt0020",
            "path": "/data[at0001]/items[at0003]"
          }
        }
      }
    },
    "rules": {
      "gt0010": {
        "id": "gt0010",
        "priority": 5,
        "when": [
          "$gt0006|Total score|<=20"
        ],
        "then": [
          "$gt0019|Risk level|=0|local::at0009|Very low risk (3.1%)|",
          "$gt0020|Recommendation|=0|local::at0004|Initiation of anti-thrombotic and invasive therapies is reasonable given a relatively low risk of major bleeding.|"
        ]
      },
      "gt0011": {
        "id": "gt0011",
        "priority": 4,
        "when": [
          "$gt0006|Total score|<=30",
          "$gt0006|Total score|>=21"
        ],
        "then": [
          "$gt0019|Risk level|=1|local::at0010|Low risk (5.5%)|",
          "$gt0020|Recommendation|=1|local::at0005|Initiation of anti-thrombotic and invasive therapies should be considered|"
        ]
      },
      "gt0015": {
        "id": "gt0015",
        "priority": 3,
        "when": [
          "$gt0006|Total score|<=40",
          "$gt0006|Total score|>=31"
        ],
        "then": [
          "$gt0019|Risk level|=2|local::at0011|Moderate risk (8.5%) |",
          "$gt0020|Recommendation|=2|local::at0006|Initiation of anti-thrombotic and invasive therapies should be considered.|"
        ]
      },
      "gt0016": {
        "id": "gt0016",
        "priority": 2,
        "when": [
          "$gt0006|Total score|<=50",
          "$gt0006|Total score|>=41"
        ],
        "then": [
          "$gt0019|Risk level|=3|local::at0012|High risk (11.9%)|",
          "$gt0020|Recommendation|=3|local::at0007|Judicious use of anti-thrombotic and invasive therapies is prudent in this high risk of bleeding group.|"
        ]
      },
      "gt0017": {
        "id": "gt0017",
        "priority": 1,
        "when": [
          "$gt0006|Total score|>50"
        ],
        "then": [
          "$gt0019|Risk level|=4|local::at0014|Very high risk (19.5%)|",
          "$gt0020|Recommendation|=4|local::at0008|Judicious use of anti-thrombotic and invasive therapies is prudent in this very high risk of bleeding group.|"
        ]
      }
    }
  },
  "ontology": {
    "term_definitions": {
      "sv": {
        "id": "sv",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "Crusade score - utvärdering",
            "description": "Utvärdering av poäng erhållen i enlighet med Crusade Score, en metod som används för att med avseende på blödningsrisk riskstratifiera patienter som genomgått STEMI eller NSTEMI i syfte att utgöra understöd för bedömning av behandling."
          },
          "gt0005": {
            "id": "gt0005",
            "text": "Poängsumma",
            "description": "Summan av samtliga faktorer."
          },
          "gt0006": {
            "id": "gt0006",
            "text": "Poängsumma",
            "description": "Summan av samtliga faktorer."
          },
          "gt0007": {
            "id": "gt0007",
            "text": "Risknivå",
            "description": ""
          },
          "gt0008": {
            "id": "gt0008",
            "text": "Rekommendation",
            "description": ""
          },
          "gt0009": {
            "id": "gt0009",
            "text": "*(en) Score"
          },
          "gt0010": {
            "id": "gt0010",
            "text": "CDS mycket låg risk"
          },
          "gt0011": {
            "id": "gt0011",
            "text": "CDS låg risk"
          },
          "gt0012": {
            "id": "gt0012",
            "text": "CDS måttlig risk"
          },
          "gt0013": {
            "id": "gt0013",
            "text": "CDS hög risk"
          },
          "gt0014": {
            "id": "gt0014",
            "text": "CDS mycket hög risk"
          },
          "gt0015": {
            "id": "gt0015",
            "text": "CDS måttlig risk"
          },
          "gt0016": {
            "id": "gt0016",
            "text": "CDS hög risk"
          },
          "gt0017": {
            "id": "gt0017",
            "text": "CDS mycket hög risk",
            "description": ""
          },
          "gt0019": {
            "id": "gt0019",
            "text": "Risknivå",
            "description": "Risknivå baserad på poäng."
          },
          "gt0020": {
            "id": "gt0020",
            "text": "Rekommendation",
            "description": ""
          }
        }
      },
      "en": {
        "id": "en",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "Crusade Score Assessment",
            "description": "Crusade score for post MI bleeding risk provides a way to stratify the risk of bleeding for patients after NSTEMI and STEMI"
          },
          "gt0005": {
            "id": "gt0005",
            "text": "Total score",
            "description": "The total score is made up of the sum of the individual scores with a range of 1 to 96"
          },
          "gt0006": {
            "id": "gt0006",
            "text": "Total score",
            "description": "The total score is made up of the sum of the individual scores with a range of 1 to 96"
          },
          "gt0007": {
            "id": "gt0007",
            "text": "Risk level",
            "description": "*"
          },
          "gt0008": {
            "id": "gt0008",
            "text": "Recommendation",
            "description": "Very High Risk: Judicious use of anti-thrombotic and invasive therapies is prudent in this very high risk of bleeding group. High risk: Judicious use of anti-thrombotic and invasive therapies is prudent in this high risk of bleeding group. Moderaterisk: Initiation of anti-thrombotic and invasive therapies should be considered and discussed with the patient as the benefits likely outweigh the risks. Low Risk: Initiation of anti-thrombotic and invasive therapies should be considered as benefits likely outweigh the risks. Very Low Risk: Initiation of anti-thrombotic and invasive therapies is reasonable given a relatively low risk of major bleeding."
          },
          "gt0009": {
            "id": "gt0009",
            "text": "Score"
          },
          "gt0010": {
            "id": "gt0010",
            "text": "Set Very low risk"
          },
          "gt0011": {
            "id": "gt0011",
            "text": "Set Low risk"
          },
          "gt0012": {
            "id": "gt0012",
            "text": "Set Moderate risk"
          },
          "gt0013": {
            "id": "gt0013",
            "text": "Set High risk"
          },
          "gt0014": {
            "id": "gt0014",
            "text": "Set Very high risk"
          },
          "gt0015": {
            "id": "gt0015",
            "text": "Set Moderate risk"
          },
          "gt0016": {
            "id": "gt0016",
            "text": "Set High risk"
          },
          "gt0017": {
            "id": "gt0017",
            "text": "Set Very high risk"
          },
          "gt0019": {
            "id": "gt0019",
            "text": "Risk level",
            "description": "Risk levels range from very low risk to very high risk"
          },
          "gt0020": {
            "id": "gt0020",
            "text": "Recommendation",
            "description": "Very High Risk: Judicious use of anti-thrombotic and invasive therapies is prudent in this very high risk of bleeding group. High risk: Judicious use of anti-thrombotic and invasive therapies is prudent in this high risk of bleeding group. Moderaterisk: Initiation of anti-thrombotic and invasive therapies should be considered and discussed with the patient as the benefits likely outweigh the risks. Low Risk: Initiation of anti-thrombotic and invasive therapies should be considered as benefits likely outweigh the risks. Very Low Risk: Initiation of anti-thrombotic and invasive therapies is reasonable given a relatively low risk of major bleeding."
          }
        }
      }
    }
  }
}